DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for Fallopian Tube Carcinoma — screening already-approved drugs against its 17-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleFallopian Tube Carcinoma maps to a 17-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for fallopian tube carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tubulin alpha 1b (TUBA1B) — TUBA1B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet gtpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6S8L · 1.801 Å · ligand GUANOSINE-5'-TRIPHOSPHATE (GTP). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
BJOG An International Journal of Obstetrics & Gynaecology · 1981 · 54 citations
PRIMARY CARCINOMA OF THE FALLOPIAN TUBE
AbstractTwenty-two patients with primary carcinoma of the Fallopian tube treated at the Royal Marsden Hospital are reported. The age distribution, parity and variety of presentation of the disease were in accordance with previous reports in the literature. Overall survival at 5 years was 48% and the place of radiotherapy and chemotherapy in its management remains to be established.
Geburtshilfe und Frauenheilkunde · 1981 · 15 citations
Das primäre Tubenkarzinom - Eine klinische Studie an 37 Patientinnen
AbstractThirty-seven cases of primary fallopian tube carcinoma treated at our institution over the years 1946 to 1976 are described. The overall 5-years survival rate was 30%, although patients with early tumors had 42% survival rate. The single most important factor affecting survival appeared to be the extent of disease at the time of diagnosis. Present treatment modalities are discussed, even though the number of tube carcinomas are few, it might be useful to adopt an official classification.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
